[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
December 1951

MONILIASIS IN PATIENTS TREATED WITH AUREOMYCIN: Clinical and Laboratory Evidence That Aureomycin Stimulates the Growth of Candida Albicans

Author Affiliations


From the Department of Dermatology, Columbia-Presbyterian Medical Center.

AMA Arch Intern Med. 1951;88(6):729-735. doi:10.1001/archinte.1951.03810120030002

AUREOMYCIN, isolated by Duggar in 1948,1 is an antibiotic biosynthesized by the actinomycete, Streptomyces aureofaciens. It has attained great clinical significance because of its therapeutic activity against a wide bacterial spectrum, which includes a number of Gram-positive and Gram-negative organisms, and it appears to be highly specific against many members of the rickettsial group and some virus-like agents.

The antibiotic is a yellow powder said to be soluble in distilled water and in 5% dextrose solution in distilled water. Solutions in isotonic sodium chloride solution precipitate when a level of more than 1% of the drug is attained. The aqueous solutions are acid and when neutralized or made alkaline deterioration of activity is rapid at room temperature.

After oral administration of a single dose of 0.5 gm., aureomycin appears in the urine in 1 hour and is detectable up to 16 hours, the peak concentration occurring between 2 and